These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 28350802

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A, Marcelin AG, Calvez V.
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [Abstract] [Full Text] [Related]

  • 3. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouédraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouédraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timité-Konan M, Leroy V, MONOD Study Group.
    BMC Med; 2017 Apr 24; 15(1):85. PubMed ID: 28434406
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.
    Cochrane Database Syst Rev; 2014 May 22; 2014(5):CD004772. PubMed ID: 24852077
    [Abstract] [Full Text] [Related]

  • 6. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
    Meyers T, Sawry S, Wong JY, Moultrie H, Pinillos F, Fairlie L, van Zyl G.
    Pediatr Infect Dis J; 2015 Feb 22; 34(2):175-9. PubMed ID: 25741970
    [Abstract] [Full Text] [Related]

  • 7. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
    Gianotti N, Cozzi-Lepri A, Antinori A, Castagna A, De Luca A, Celesia BM, Galli M, Mussini C, Pinnetti C, Spagnuolo V, d'Arminio Monforte A, Ceccherini-Silberstein F, Andreoni M, Icona Foundation Study and mono-PI/r database Study Cohorts.
    PLoS One; 2017 Feb 22; 12(2):e0171611. PubMed ID: 28192453
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.
    AIDS; 2009 Sep 10; 23(14):1829-40. PubMed ID: 19474650
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C, Valer L, Ribera E, Barreiro P, Martín-Carbonero L, Ramirez G, Soriano V.
    HIV Clin Trials; 2006 Sep 10; 7(4):163-71. PubMed ID: 17065028
    [Abstract] [Full Text] [Related]

  • 15. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.
    HIV Clin Trials; 2011 Sep 10; 12(5):255-67. PubMed ID: 22180523
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
    Gondrie IPE, Bastiaans DET, Fraaij PLA, Driessen GJA, van der Knaap LC, Visser EG, van Jaarsveld P, de Groot R, Hartwig NG, Burger DM, van Rossum AMC.
    Pediatr Infect Dis J; 2017 Oct 10; 36(10):976-980. PubMed ID: 28475554
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A, ARCA Collaborative Group.
    J Med Virol; 2010 Dec 10; 82(12):1996-2003. PubMed ID: 20981785
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.